4 January, 2024

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial

2024-04-01T11:51:43+03:00By |Categories: Multicenter studies in Greece, Publications, Therapeutics|Tags: , , |

Evangelos J. Giamarellos-Bourboulis, Athanasios Siampanos, Amalia Bolanou, Sarantia Doulou, Nikolaos Kakavoulis, Konstantinos Tsiakos, Sokratis Katopodis, Georgios Schinas, Lamprini Skorda, Zoi Alexiou, Konstantinos Armenis, Paraskevi Katsaounou, George Chrysos, Aikaterini Masgala, Garyphalia Poulakou, Nikolaos Antonakos, Asimina Safarika, Miltiades Kyprianou, Konstantina Dakou, Styliani Gerakari, Ilias C Papanikolaou, Prof Haralampos Milionis, Prof Markos Marangos, Prof George N Dalekos,

18 June, 2022

Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial

2023-02-16T12:38:06+03:00By |Categories: Publications|Tags: , , |

Eleni Karakike, Brendon P Scicluna, Maria Roumpoutsou, Ioannis Mitrou, Niki Karampela, Athanasios Karageorgos, Konstantinos Psaroulis, Eleni Massa, Achillefs Pitsoulis, Panagiotis Chaloulis, Evanthia Pappa, Irene T Schrijver, Frantzeska Frantzeskaki, Malvina Lada, Nicolas Dauby, David De Bels, Ioannis Floros, Souzana Anisoglou, Eleni Antoniadou, Maria Patrani, Glykeria Vlachogianni, Eleni Mouloudi, Anastasia Antoniadou, David Grimaldi, Thierry Roger, W

1 December, 2021

Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial

2023-02-16T13:22:30+03:00By |Categories: Publications|Tags: , , |

Konstantinos Tsiakos, Antonios Tsakiris, Georgios Tsibris, Pantazis-Michael Voutsinas, Periklis Panagopoulos, Maria Kosmidou, Vasileios Petrakis, Areti Gravvani, Theologia Gkavogianni, Eleftherios Klouras, Konstantina Katrini, Panagiotis Koufargyris, Iro Rapti, Athanassios Karageorgos, Emmanouil Vrentzos, Christina Damoulari, Vagia Zarkada, Chrysanthi Sidiropoulou, Sofia Artemi, Anastasios Ioannidis, Androniki Papapostolou, Evangelos Michelakis, Maria Georgiopoulou, Dimitra-Melia Myrodia, Panteleimon Tsiamalos, Konstantinos Syrigos, George Chrysos,

1 September, 2021

The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece

2024-04-02T18:01:32+03:00By |Categories: Publications, Therapeutics|Tags: , , |

Evangelos J. Giamarellos-Bourboulis, George L Daikos, Panagiotis Gargalianos, Charalambos Gogos, Marios Lazanas, Periklis Panagopoulos, Garyphallia Poulakou, Helen Sambatakou, Michael Samarkos Infectious Diseases and Therapy 2021 Sep;10(3):1081-1095 DOI: 10.1007/s40121-021-00471-1Download pdf 🡇 Funding The study was funded by the Hellenic Institute for the Study of Sepsis. No Rapid Service Fee was received by the

1 January, 2021

ACCESS

2024-02-07T15:52:51+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title A randomized clinical trial of oral Clarithromycin in Community-acquired pneumonia to attenuatE inflammatory responseS and improve outcomeS Brief Description Based on evidence coming from observational studies that addition of macrolides in the treatment regimen of community-acquired pneumonia (CAP) exhibits some anti-inflammatory mode of action, this RCT is aiming to

1 May, 2020

ACHIEVE

2023-01-09T12:17:31+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title Anti-inflammatory ClaritHromycin to ImprovE SARS-CoV-2 (COVID-19) infection Early: The ACHIEVE open-label non-randomized clinical trial Brief Description ACHIEVE is an open non-randomized clinical trial aiming to prove that the addition of oral clarithromycin to treatment regimen of COVID-19 is associated with early clinical improvement and attenuation of the high inflammatory

1 January, 2020

Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study

2023-02-16T14:31:00+03:00By |Categories: Publications, Therapeutics|Tags: , , |

Evdoxia Kyriazopoulou, Dimitrios Sinapidis, Stamatios Halvatzis, Dimitrios Velissaris, Nikolaos Alexiou, Vasilios Kosmas, Maria-Evangelia Adami, Miltiades Kyprianou, Aikaterini Kyprianou, Aggelos Stefos, Malvina Lada, Pantelis Koutoukas, Maria Pavlaki, Anna Kyriakoudi, Anna Makina, Charalambos Gogos, Michael S Niederman, Evangelos J. Giamarellos-Bourboulis International Journal of Antimicrobial Agents 2020 Jan;55(1):105836 DOI: 10.1016/j.ijantimicag.2019.10.017View article 🡇 Funding The works were

1 December, 2017

INCLASS

2023-01-09T12:15:00+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title A double-blind, randomized, placebo-controlled clinical study of the efficacy of INtravenous CLArithromycin as adjunctive treatment in patients with Sepsis and respiratory and multiple organ dysfunction Syndrome Brief Description INCLASS is a randomized clinical trial aiming to compare the efficacy of intravenous clarithromycin over placebo in patients with sepsis and

23 May, 2016

Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis

2023-02-16T15:31:14+03:00By |Categories: Other Grants, Publications|Tags: , |

Thomas Tsaganos, Maria Raftogiannis, Maria Pratikaki, Sofia Christodoulou, Anastasia Kotanidou, Evangelos Papadomichelakis, Apostolos Armaganidis, Christina Routsi, Evangelos J. Giamarellos-Bourboulis Antimicrobial Agents and Chemotherapy 2016 May 23;60(6):3640-6 DOI: 10.1128/AAC.02974-15View article 🡇 Funding The study was funded by the Hellenic Institute for the Study of Sepsis. Keywords: pneumonia; sepsis

Go to Top